Future Science OA最新文献_第3页

Modifiable risk factors of dementia in the Indian scenario. 在印度的情况下，痴呆的可改变的危险因素。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-03-24 DOI: 10.1080/20565623.2025.2483132

Ankul Singh S, Lakshmi Chandran, Chitra Vellapandian

引用次数: 0

Reply to the letter to the editor: previous immunological disease can promote neurological complications of SARS-CoV-2 infection, such as VST or GBS. 回复编辑来信：既往免疫性疾病可促进SARS-CoV-2感染的神经系统并发症，如VST或GBS。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-17 DOI: 10.1080/20565623.2025.2463851

Shema Ayadi, Hela Jamoussi

引用次数: 0

The association between whole blood viscosity and CHA2DS2-VASc/CHA2DS2-VA scores in patients with atrial fibrillation. 房颤患者全血粘度与CHA2DS2-VASc/CHA2DS2-VA评分的关系

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-02-18 DOI: 10.1080/20565623.2025.2467607

Erkan Kahraman, Koray Kalenderoglu

{"title":"The association between whole blood viscosity and CHA2DS2-VASc/CHA2DS2-VA scores in patients with atrial fibrillation.","authors":"Erkan Kahraman, Koray Kalenderoglu","doi":"10.1080/20565623.2025.2467607","DOIUrl":"10.1080/20565623.2025.2467607","url":null,"abstract":"Introduction: CHA2DS2-VASc and CHA2DS2-VA scores are often used to demonstrate thromboembolic risk in nonvalvular atrial fibrillation. Elevated whole blood viscosity is an independent risk factor for ischemic stroke.Objective: This study aimed to ascertain the correlation between whole blood viscosity and CHA2DS2-VASc/CHA2DS2-VA scores.Methods: This study was performed retrospectively in a tertiary cardiac facility, encompassing 150 patients.Results: The study's results demonstrate that whole blood viscosity, concerning both high shear rate and low shear rate variables, are statistically significant in forecasting the likelihood of elevated CHA2DS2-VA and CHA2DS2-VASc scores. (AUC: 0.690, 0.693; p: <0.001; 0.647, 0.665; p: <0.05).Conclusion: Whole blood viscosity had a substantial correlation with the CHA2DS2-VASc/CHA2DS2-VA scores in patients with atrial fibrillation and may be used to evaluate thromboembolism risk, akin to these scores.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2467607"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11845118/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143448798","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Assessing pharmacists' knowledge, attitudes, and practices on medicines waste reduction in the UAE. 评估阿联酋药剂师在减少药品浪费方面的知识、态度和做法。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-04 DOI: 10.1080/20565623.2025.2526952

Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Moyad Shahwan, Mena Al-Ani, Mustafa Aal Yaseen, Hoor Hamidoglu, Heba M Mohamed, Ammar Ali Saleh Jaber

{"title":"Assessing pharmacists' knowledge, attitudes, and practices on medicines waste reduction in the UAE.","authors":"Ammar Abdulrahman Jairoun, Sabaa Saleh Al-Hemyari, Moyad Shahwan, Mena Al-Ani, Mustafa Aal Yaseen, Hoor Hamidoglu, Heba M Mohamed, Ammar Ali Saleh Jaber","doi":"10.1080/20565623.2025.2526952","DOIUrl":"10.1080/20565623.2025.2526952","url":null,"abstract":"Objectives: Global concerns were focused on the improper disposal of unwanted medications and using out-of-date medicines. This study aims to assess pharmacists' knowledge, attitudes, and practices regarding this issue, recognizing the role pharmacies can play as local collection points for the safe disposal of unwanted medications.Methods: A cross-sectional study design including a random sample of 603 pharmacists responded to the questionnaire via face-to-face interview. Multivariate logistic regression models determined significant factors affecting the knowledge, attitudes, and practices of pharmacists.Results: The levels of knowledge, attitudes, and practices were generally low. Only 32.8% showed good knowledge, 17.7% had positive attitudes, and 32% exhibited good practices. Certain demographic factors were positively associated with higher levels of knowledge, attitudes, and practices. These include male pharmacists, longer duration of experience, working in a chain pharmacy, working as a chief pharmacist, and receiving training about environmental impact and waste management.Conclusion: This study illustrated serious gaps in knowledge and practices among community pharmacists in the United Arab Emirates regarding medicines waste reduction. Despite awareness, nearly half had poor knowledge, and best practices were inconsistently implemented. Proper educational campaigns and courses, comprehensive training, and policy interventions are essential to address these gaps.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2526952"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233820/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567343","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

GC-MS analysis, comprehensive biological profiling, molecular docking and ADMET studies of Ficus vasta Forssk. n-hexane extract. fusius vasta Forssk的GC-MS分析、综合生物学分析、分子对接和ADMET研究。正己烷提取。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-06 DOI: 10.1080/20565623.2025.2527021

Hanan Y Aati, Abdul Rauf, Jawahir Al-Qatani, Bilal Ahmad Ghalloo, Areej Al-Tweel, Mona Khwery, Huma Rao, Muhammad Sajid-Ur-Rehman, Kashif-Ur-Rehman Khan

{"title":"GC-MS analysis, comprehensive biological profiling, molecular docking and ADMET studies of Ficus vasta Forssk. n-hexane extract.","authors":"Hanan Y Aati, Abdul Rauf, Jawahir Al-Qatani, Bilal Ahmad Ghalloo, Areej Al-Tweel, Mona Khwery, Huma Rao, Muhammad Sajid-Ur-Rehman, Kashif-Ur-Rehman Khan","doi":"10.1080/20565623.2025.2527021","DOIUrl":"10.1080/20565623.2025.2527021","url":null,"abstract":"Aims: Ficus vasta Forssk. is a valuable but relatively less explored medicinal and edible plant. This study focused on analyzing the biochemical properties, molecular docking, and ADMET profiling of its n-hexane extract (NHFV).Materials and methods: Phytochemical screening was performed using GC-MS and total bioactive content assays (TPC, TFC, and TTC). Antioxidant potential (NOS and TAC), antiurease, antityrosinase, and hemolytic activities were also assayed. Molecular docking was performed for GC-MS identified ligands against urease and tyrosinase. ADMET investigation was performed to assess drug-likeness and safety profiles.Results: NHFV showed significant concentration of TPC (48.01 ± 0.73 mg GA.Eq.g-1), TFC (65.33 ± 0.67 mg QU.Eq.g-1), and TTC (3.45 ± 0.31 mg TA.Eq.g-1). GC-MS analysis identified 43 phytochemicals. Antioxidant assays revealed 91.34 ± 0.86 mg AA.Eq.g-1 NOS and 72.90 ± 0.10 mg AA.Eq.g-1 TAC activity. The extract showed 4.64 ± 0.08% hemolysis, 60.20 ± 1.39% urease, and 75.61 ± 0.64% tyrosinase inhibition. Docking results revealed Cycloartenol (-8.2 kcal/mol) and Lupeol acetate (-8.3 kcal/mol) as potent inhibitors, surpassing standard agents.Conclusion: NHFV possesses prominent antioxidant, antiulcer, and skin-whitening potential. Molecular docking and ADMET data support its therapeutic relevance and potential for future drug design.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2527021"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233824/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567344","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Integrating artificial intelligence in healthcare: applications, challenges, and future directions. 在医疗保健中集成人工智能：应用、挑战和未来方向。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-04 DOI: 10.1080/20565623.2025.2527505

Peng Lean Chong, Vikneswaran Vaigeshwari, Basir Khan Mohammed Reyasudin, Binti Ros Azamin Noor Hidayah, Purnshatman Tatchanaamoorti, Jian Ai Yeow, Feng Yuan Kong

{"title":"Integrating artificial intelligence in healthcare: applications, challenges, and future directions.","authors":"Peng Lean Chong, Vikneswaran Vaigeshwari, Basir Khan Mohammed Reyasudin, Binti Ros Azamin Noor Hidayah, Purnshatman Tatchanaamoorti, Jian Ai Yeow, Feng Yuan Kong","doi":"10.1080/20565623.2025.2527505","DOIUrl":"10.1080/20565623.2025.2527505","url":null,"abstract":"Artificial intelligence (AI) has demonstrated remarkable potential in transforming medical diagnostics across various healthcare domains. This paper explores AI applications in cancer detection, dental medicine, brain tumor database management, and personalized treatment planning. AI technologies such as machine learning and deep learning have enhanced diagnostic accuracy, improved data management, and facilitated personalized treatment strategies. In cancer detection, AI-driven imaging analysis aids in early diagnosis and precise treatment decisions. In dental healthcare, AI applications improve oral disease detection, treatment planning, and workflow efficiency. AI-powered brain tumor databases streamline medical data management, enhancing diagnostic precision and research outcomes. Personalized treatment planning benefits from AI algorithms that analyze genetic, clinical, and lifestyle data to recommend tailored interventions. Despite these advancements, AI integration faces challenges related to data privacy, algorithm bias, and regulatory concerns. Addressing these issues requires improved data governance, ethical frameworks, and interdisciplinary collaboration among healthcare professionals, researchers, and policymakers. Through comprehensive validation, educational initiatives, and standardized protocols, AI adoption in healthcare can enhance patient outcomes and optimize clinical decision-making, advancing the future of precision medicine and personalized care.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2527505"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12233828/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144567345","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma. 卡非佐米与伊唑唑米治疗复发和难治性多发性骨髓瘤的药物经济学评价

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-06-18 DOI: 10.1080/20565623.2025.2514969

Lin Wang, Fen Chen, Yuanyuan Ma, Xihan Lin, Jinyu Liu, Yu Zhang, Ruxu You

{"title":"Pharmacoeconomic evaluation of carfilzomib versus ixazomib for the treatment of relapsed and refractory multiple myeloma.","authors":"Lin Wang, Fen Chen, Yuanyuan Ma, Xihan Lin, Jinyu Liu, Yu Zhang, Ruxu You","doi":"10.1080/20565623.2025.2514969","DOIUrl":"10.1080/20565623.2025.2514969","url":null,"abstract":"Objective: This study assesses the cost-effectiveness of carfilzomib plus lenalidomide and dexamethasone (KRd) versus ixazomib plus lenalidomide and dexamethasone for relapsed and refractory multiple myeloma (RRMM) in China.Methods: A survival model was used to analyze health states and costs over a lifetime, with a 4-week cycle. Treatment effects on progression-free survival (PFS) and overall survival (OS) were modeled using hazard ratios (HRs) derived from the network meta-analysis (NMA). Health state utility values and disutility values for adverse events were obtained from published literature. Direct medical costs included drug costs, disease management costs, and costs associated with adverse event management. Costs and utilities were discounted by 5% annually. Both one-way and probabilistic sensitivity analyses were conducted.Results: The carfilzomib combination was found to be cost-effective, saving $127,513.22 per additional quality-adjusted life year (QALY) gained compared to the ixazomib combination. Sensitivity analysis showed that ixazomib's price, progression state utility, and carfilzomib's price significantly affected the results. At a $40,023.27 willingness-to-pay (WTP) threshold, the carfilzomib combination has a 100% probability of being cost-effective.Conclusions: The study shows that, based on evidence from indirect comparisons, KRd is a cost-effective treatment option for RRMM patients in China.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2514969"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12184143/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144325150","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Spectrophotometric analysis of artesunate injections available in community pharmacies in Northern and Western Uganda. 乌干达北部和西部社区药房提供的青蒿琥酯注射剂的分光光度分析。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-06-12 DOI: 10.1080/20565623.2025.2511444

Ebere Emilia Ayogu, Emmanuel Aryon Ngolryeko, Joseph Obiezu Chukwujekwu Ezeonwumelu, Ibrahim Garba Wawata, Bashir Olaniyi Sadiq

{"title":"Spectrophotometric analysis of artesunate injections available in community pharmacies in Northern and Western Uganda.","authors":"Ebere Emilia Ayogu, Emmanuel Aryon Ngolryeko, Joseph Obiezu Chukwujekwu Ezeonwumelu, Ibrahim Garba Wawata, Bashir Olaniyi Sadiq","doi":"10.1080/20565623.2025.2511444","DOIUrl":"10.1080/20565623.2025.2511444","url":null,"abstract":"Aim: The surge in different brands of artesunate injection in Uganda, has raised the need for this study, which aimed at quantifying the actual amount of artesunate in different brands of artesunate injections available in Northern and Western Uganda.Materials and methods: The wavelength at maximum absorbance of pure artesunate powder was determined using Ultraviolet-visible spectrophotometer and Beer Lambert's plot was generated. This was validated and used to assay 27 brands of artesunate.Results: In the spectrophotometric assay method used, Beer Lambert's law was obeyed within the range of 20 µg/ml-140 µg/ml with linear regression equation of y = 0.012 + 0.030 and correlation coefficient of (R2) 0.999 (n = 9). The limits of detection (sensitivity) and quantification were found to be 0.83 mg/ml and 2.09 mg/ml respectively. About 66.6% (18) and 33.3% (9) had actual artesunate content higher and lower than labeled claim respectively, while 40.7% (11) had deviations from labeled claim that were within acceptable limits.Conclusion: Most brands of artesunate injection assayed deviated from labeled claim, regional/environmental factor impacted much on the stability of artesunate thus there is need for further screening of the quality of artesunate injection in circulation in view of the therapeutic consequences of substandard artesunate injection.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2511444"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12164379/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144274678","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma. 晚期或转移性食管鳞状细胞癌的化疗免疫治疗序贯放疗。

IF 2.4

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-07-16 DOI: 10.1080/20565623.2025.2527497

Xiang Han, Zhongfa Zhang, Ling Zhang, Yunhong You, Xiajuan Xu, Yuchao Niu, Zhimei Zhao, Xiuhui Guo, Youxin Ji, Qiuyu Hou, Keke Nie

{"title":"Chemo-immunotherapy sequential with radiotherapy in advanced or metastatic esophageal squamous cell carcinoma.","authors":"Xiang Han, Zhongfa Zhang, Ling Zhang, Yunhong You, Xiajuan Xu, Yuchao Niu, Zhimei Zhao, Xiuhui Guo, Youxin Ji, Qiuyu Hou, Keke Nie","doi":"10.1080/20565623.2025.2527497","DOIUrl":"10.1080/20565623.2025.2527497","url":null,"abstract":"Background: To evaluate the efficacy and safety of chemo-immunotherapy combined with residual lesions irradiation of advanced stage esophageal squamous cell carcinoma.Methods: Treatment-naïve patients with radiologically and histologically confirmed advanced or metastatic squamous-cell esophageal carcinoma were enrolled. Participants received four cycles of the TP regimen combined with the PD-1 inhibitor sintilimab. Patients who completed four cycles of chemo-immunotherapy with stable disease (SD) or partial response (PR) subsequently received 50 Gy of radiation in 25 fractions for residual tumors. Maintenance sintilimab therapy was administered every 21 days for up to 31 cycles or until disease progression or intolerable toxicity occurred.Results: A total of 39 patients were enrolled in this study, of whom 30 were evaluable for efficacy and toxicity. The complete response (CR) rate was 6.7% (2/30), the partial response (PR) rate was 53.3% (16/30). The median depth of response (DpR) was 34.5% for chemo-immunotherapy and increased to 64.0% after radiotherapy. The progression-free survival (PFS) was 16.4 months, while overall survival (OS) has not yet been reached.Conclusions: Chemo-immunotherapy followed by radiotherapy for residual tumors and maintenance sintilimab, demonstrated high response rates, prolonged PFS, and tolerable toxicity as a first-line treatment for patients with advanced or metastatic esophageal squamous-cell carcinoma.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2527497"},"PeriodicalIF":2.4,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12269676/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144642284","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Wearable sensor data visualization for patient monitoring and management: a Cancer Wellness application in Vietnam. 用于患者监测和管理的可穿戴传感器数据可视化：越南癌症健康应用。

IF 2.1

Future Science OA Pub Date : 2025-12-01 Epub Date: 2025-08-02 DOI: 10.1080/20565623.2025.2541522

Huyen Thi Hoa Nguyen, Tran Ngoc Tran, Giang Huong Nguyen, Tung Truong Nguyen, Ngan Thi Thuy Nguyen, Hieu Huy Pham, Linh Khanh Bui, Anh Chau Nguyen, Debra J Anderson

{"title":"Wearable sensor data visualization for patient monitoring and management: a Cancer Wellness application in Vietnam.","authors":"Huyen Thi Hoa Nguyen, Tran Ngoc Tran, Giang Huong Nguyen, Tung Truong Nguyen, Ngan Thi Thuy Nguyen, Hieu Huy Pham, Linh Khanh Bui, Anh Chau Nguyen, Debra J Anderson","doi":"10.1080/20565623.2025.2541522","DOIUrl":"10.1080/20565623.2025.2541522","url":null,"abstract":"Background: This study incorporates Fitbit wearable sensor technology into a mobile application named Cancer Wellness Program (CWP) for patient monitoring. The objective of this study is to explore the experiences of healthcare providers in using the CWP application for managing symptoms of people with cancer and in delivering health education programs. Methods: A qualitative study design with a purposive sampling approach was employed, using a structured, in-depth interview method to involve 15 healthcare workers. Results: Key features of the CWP application include a patient education platform, a dashboard to monitor patient health data and learning progress, and interactive communication between the two parties. Multiple advantages of this application were identified by healthcare providers, namely user-friendliness, data aggregation and personalization. Conclusion: Despite minor technical drawbacks, the CWP application proves to be a powerful assistant for healthcare providers to optimize patient care.","PeriodicalId":12568,"journal":{"name":"Future Science OA","volume":"11 1","pages":"2541522"},"PeriodicalIF":2.1,"publicationDate":"2025-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12320870/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144768607","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0